Printer Friendly

Reportlinker Adds Prostate Cancer - US Drug Forecasts and Treatment Analysis to 2020.

NEW YORK, Dec. 8, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Prostate Cancer - US Drug Forecasts and Treatment Analysis to 2020

http://www.reportlinker.com/p0332352/Prostate-Cancer---US-Drug-Forecasts-and-Treatment-Analysis-to-2020.html

Prostate Cancer - US Drug Forecasts and Treatment Analysis to 2020

Summary

GlobalData's pharmaceutical report, "Prostate Cancer - US Drug Forecasts and Treatment Analysis to 2020" is an essential source of information and analysis on the US prostate cancer therapeutics market. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the key trends shaping and driving the US prostate cancer therapeutics market, and analyzes the treatment usage patterns. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer sector. It quantifies the unmet need in the US prostate cancer therapeutics market, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The scope of the report includes:

- An overview of prostate cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.

- Annualized US prostate cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020.

- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.

- Competitor assessment including drug launch analysis and drug sales forecasts.

- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM (Life Cycle Management) activities and drug sales forecast.

- Analysis of unmet need in the market and target product profiles including opportunity for target products.

- Technology trends analytic framework to assess the strength of the pipeline.

- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, tyrosine kinase inhibitor, angiogenesis inhibitors and others.

- An overview of the most promising drugs including clinical study details, efficacy, safety, collaboration agreements, marketing rights and launch analysis.

- Analysis of the current and future market competition in the US Prostate Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Sanofi-aventis, Pfizer, Inc., AstraZeneca PLC, Bristol-Myers Squibb, Medivation, Takeda Pharmaceuticals and Dendreon Corporation.

- Analysis of licensing agreements during 2004-2010 in the prostate cancer therapeutics market. Merger and Acquisition (M&A analysis) which includes M&A deals by size and geography.

- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.

- Direct quotes from key opinion leaders (KOL) or physicians in the prostate cancer therapeutics market in the US.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

- Develop business strategies and perform superior market quantification analysis by

- Understanding the trends shaping and driving the US prostate cancer therapeutics market.

- Understanding the treatment preferences of physicians for each disease state and across treatment flow.

- Accessing market sizing forecasts and quantified growth opportunities in the US prostate cancer therapeutics market up to 2020.

- Quantifying the patient population in the US to better design product pricing and launch plans.

- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by

- Performing benchmarking analysis and growth opportunities against currently marketed products.

- Identifying market entry points based on safety, efficacy, and pricing parameters.

- Assessing competitiveness of products in the market by understanding the strengths and weaknesses of current competition.

- Develop and design your in-licensing and out-licensing strategies by

- Taking a comprehensive look at the disease pipeline and identifying the most promising paradigm-shifting products.

- Assessing the strength of pipeline based on first-in-class, me-too and generic products and their lifecycle management.

- Track drug sales in the US prostate cancer therapeutics market from 2001 to 2020.

- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.

- What's the next big thing in the US prostate cancer therapeutics market landscape? Identify, understand and capitalize.

1 Table of Contents 4

1.1 List of Tables 7

1.2 List of Figures 8

2 Disease Overview 10

2.1 Overview 10

2.1.1 TNM (Tumor, Nodes, Metastasis) Staging System 10

2.1.2 Jewett-Whitmore system 11

2.2 Epidemiology 12

2.3 Etiology 12

2.4 Symptoms 12

2.4.1 Localized or Locally Advanced Prostate Cancer 12

2.4.2 Metastatic Prostate Cancer 13

2.5 Diagnosis 13

2.5.1 Digital Rectal Examination 13

2.5.2 Prostate Specific Antigen Test 14

2.5.3 Transrectal Ultrasound 14

2.5.4 Prostate Biopsy 14

2.6 Pathology 15

2.6.1 Grading 15

2.7 Treatment 15

2.7.1 Watchful Waiting 15

2.7.2 Radiation therapy 15

2.7.3 Surgery 16

2.7.4 Hormone therapy 17

2.7.5 Chemotherapy Options 18

2.7.6 Other Treatments Being Studied 19

2.8 Treatment Guidelines 19

3 Market Characterization 20

3.1 The US 20

3.1.1 Market Size 20

3.1.2 Drivers and Restraints 27

3.1.3 Forecasts 30

3.1.4 Drug Sales 35

3.1.5 Pricing & Reimbursements 39

4 Competitor Assessment 40

4.1 Strategic Competitor Assessment 40

4.1.1 Overview 40

4.1.2 Benchmarking 40

4.1.3 Current Competitor Assessment 44

4.2 Launch Analysis and Sales Forecasts 46

4.3 Product Profiles 47

4.3.1 Taxotere (docetaxel) 48

4.3.2 Casodex (Bicalutamide) 52

4.3.3 Zoladex (Goserelin) 57

4.3.4 Provenge (sipuleucel-T) 59

4.3.5 Jevtana (cabazitaxel) 61

4.3.6 Eligard (leuprolide acetate) 63

4.3.7 Lupron (Leuprolide acetate) 68

4.3.8 Firmagon (degarelix) 72

4.3.9 Vantas (Histrelin) 74

4.3.10 Novantrone (Mitoxantrone hydrochloride) 76

4.3.11 Emcyt (estramustine) 78

4.3.12 Trelstar (triptorelin) 79

4.3.13 Eulexin 82

4.3.14 Delestrogen 84

4.3.15 Gynodiol 85

4.3.16 Estrace tablet 86

4.3.17 Tace 87

4.3.18 Nilandrone 88

4.3.19 Premarin 89

4.3.20 Sales Forecast for Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol 90

5 Pipeline Assessment 91

5.1 Overview 91

5.2 Pipeline Analysis by Phase of Development 92

5.3 Pipeline by Mechanism of Action 93

5.4 Strategic Pipeline Assessment 94

5.4.1 Technology Trends Analytical Framework 94

5.5 Trends in Prostate Cancer Pipeline 95

5.5.1 More Clarity on the Origin of Prostate Cancer Will Help in Identifying Novel Targets for Prostate Cancer Drugs 95

5.5.2 Molecules with Novel Mechanism of Action Strengthening Prostate Cancer Pipeline 95

5.5.3 Failure of Key Molecules to Achieve Positive Results in Phase III Development 95

5.6 Partners in Research and Development 96

5.6.1 Licensing Agreements by Phase of Development 96

5.6.2 Licensing Agreements by Geography 99

5.6.3 Licensing Agreements: Technology Licensing Agreements in Prostate Cancer 99

5.7 Most Promising Drugs' Profiles 101

5.7.1 Aflibercept (VEGF Trap) 102

5.7.2 Ipilimumab 104

5.7.3 Abiraterone Acetate (CB7630) 107

5.7.4 Zibotentan (ZD4054) 110

5.7.5 Sprycel (dasatinib) 112

5.7.6 MDV3100 114

5.8 Prostate Cancer Pipeline - Pre-clinical Phase 117

5.9 Prostate Cancer Pipeline - Phase I 119

5.10 Prostate Cancer Pipeline - Phase II 122

5.11 Prostate Cancer Pipeline - Phase III 130

5.12 Key Takeaway 132

6 Unmet Need and Target Product Profile 133

6.1 Unmet Need 135

6.1.1 Hormone-independent Metastatic Prostate Cancer Therapy 135

6.1.2 Hormone-dependent Metastatic Prostate Cancer Therapy 136

6.2 Opportunity for Target Product 137

6.3 Target Product Profile 139

6.3.1 Ideal Characteristics 139

6.3.2 Target Product Description 140

6.4 Key Takeaway 140

7 Strategic Assessment 141

7.1 Key Events Impacting the Future Market 141

7.2 Market Impact Analysis 142

7.3 Future Market Scenario 142

7.4 Company Analysis 144

7.4.1 Market Leadership 144

7.4.2 Future Players in the Market 144

7.5 Key Takeaway 145

8 Company Profiles 146

8.1 Sanofi-aventis 146

8.1.1 Business Description 146

8.1.2 Financial Overview 148

8.1.3 SWOT Analysis 148

8.1.4 Oncology Focus 153

8.2 Pfizer Inc. 153

8.2.1 Business Description 153

8.2.2 Financial Overview 154

8.2.3 SWOT Analysis 155

8.2.4 Oncology Focus 161

8.3 AstraZeneca 163

8.3.1 Business Description 163

8.3.2 Financial Overview 165

8.3.3 SWOT Analysis 165

8.3.4 Oncology Focus 169

8.4 Bristol-Myers Squibb 171

8.4.1 Business Description 171

8.4.2 Financial Overview 172

8.4.3 SWOT Analysis 172

8.4.4 Oncology Focus 178

8.5 Medivation 180

8.5.1 Business Description 180

8.5.2 SWOT Analysis 180

8.5.3 Oncology Focus 183

8.6 Takeda Pharmaceuticals 183

8.6.1 Business Description 183

8.6.2 SWOT Analysis 184

8.7 Dendreon Corporation 186

8.7.1 Business Description 186

8.7.2 SWOT Analysis 186

8.8 Johnson and Johnson 189

8.8.1 Business Description 189

8.8.2 SWOT Analysis 191

8.8.3 Oncology Focus 197

8.9 Auron Healthcare GmbH 198

8.9.1 Business Description 198

8.10 Oncogenex Pharmaceuticals, Inc. 198

8.10.1 Business Description 198

8.11 Agennix AG 198

8.11.1 Business Description 198

8.12 GTx, Inc. 199

8.12.1 Business Description 199

8.13 GlaxoSmithKline plc. 199

8.13.1 Business Description 199

8.13.2 Financial Overview 200

8.13.3 SWOT Analysis 200

8.13.4 Oncology Focus 206

9 M&A Analysis 208

9.1 Key Highlights 208

9.2 Key Deals' Analysis 209

9.2.1 Johnson & Johnson Acquires Cougar Biotechnology 209

9.2.2 Endo Pharmaceuticals Acquires Indevus Pharmaceuticals 209

9.2.3 Tolmar Holding Acquires QLT USA from QLT 210

9.2.4 Biomarin Pharmaceutical to Acquire Lead therapeutics 210

9.2.5 Isis Pharmaceuticals Reacquires Rights to Cancer Drug from Eli Lilly & Co. 210

9.2.6 Quest PharmaTech Acquires Late-stage Immunotherapeutic Antibody Pipeline from Paladin Labs 210

9.2.7 VaxOnco Acquires Rights to Onyvax-P Cell Vaccine From Onyvax 210

9.2.8 GPC Biotech Merges with Agennix 210

9.2.9 Eli Lilly Acquires ImClone 211

9.2.10 BBM Holdings Acquires YM BioSciences 211

9.2.11 Sagent Pharmaceuticals Acquires Injectable Generic Drug Applications of Spectrum Pharmaceuticals 211

9.3 M&A Deals by Geography 212

9.4 M&A Deals by Deal Size 212

10 Expert Opinion 213

10.1 US 213

11 Appendix 215

11.1 Market Definitions 215

11.2 Abbreviations 215

11.3 Research Methodology 217

11.3.1 Coverage 217

11.3.2 Secondary Research 218

11.3.3 Forecasting 218

11.3.4 Primary Research 220

11.3.5 Expert Panel validation 221

11.4 Contact Us 221

11.5 Disclaimer 221

11.6 Sources 2221.1 List of Tables

Table 1: Prostate Cancer Therapeutics Market, Global, Staging of the Prostate Cancer, 2010 11

Table 2: Prostate Cancer, Global, Age Related PSA Levels (ng/ml), 2010 14

Table 3: Prostate Cancer Therapeutics Market, US, Sales Value ($bn), 2001-2009 20

Table 4: Prostate Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2001-2009 22

Table 5: Prostate Cancer Therapeutics Market, US, Patient Volume ('000s), 2001-2009 23

Table 6: Prostate Cancer Therapeutics Market, The US, Treatment Usage Patterns ('000s), 2001-2009 25

Table 7: Prostate Cancer Therapeutics Market, US, Sales Value ($m), 2009-2020 30

Table 8: Prostate Cancer, US, Annual Cost of Therapy ($), 2009-2020 31

Table 9: Prostate Cancer Therapeutics Market, US, Patient Volume ('000s), 2009-2020 32

Table 10: Prostate Cancer Therapeutics Market, US, Treatment Usage Patterns ('000s), 2009-2020 33

Table 11: Prostate Cancer Therapeutics Market, US, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2010 37

Table 12: Prostate Cancer Therapeutics Market, US, Hormone-refractory Prostate Cancer Drug Sales ($m), 2011-2020 37

Table 13: Prostate Cancer, Global, Clinical Endpoints for Benchmarking, 2010 41

Table 14: Prostate Cancer, Global, Chemotherapy, Safety Profile of Standard Care Treatment, 2010 42

Table 15: Prostate Cancer, Global, Hormone Therapy, Safety Profile of Standard Care Treatment, 2010 43

Table 16: Prostate Cancer, US, Benchmarking Major Marketed Products, 2010 47

Table 17: Prostate Cancer, Global, Casodex, Incidence of Adverse Effects, 2010 53

Table 18: Prostate Cancer, Global, Eligard, Effect on PSA Level, 2010 64

Table 19: Prostate Cancer, Global, Eligard, Incidence of Adverse Effects, 2010 65

Table 20: Prostate Cancer, Global, Eligard, Regulatory Approval by Region 66

Table 21: Prostate Cancer, Global, Lupron, Efficacy End Point for Three Products 68

Table 22: Prostate Cancer, Global, Lupron, Incidence of Adverse Effects, 2010 69

Table 23: Prostate Cancer, Global, Licensing Agreements, 2009-2010 98

Table 24: Prostate Cancer, Global, Technology Licensing Agreements Description, 2010 100

Table 25: Prostate Cancer, Global, Most Promising Drugs Under Clinical Development, 2010 101

Table 26: Prostate Cancer, Global, Pre-clinical Phase Pipeline, August 2010 117

Table 27: Prostate Cancer, Global, Phase I Pipeline, August 2010 119

Table 28: Prostate Cancer, Global, Phase II Pipeline, August 2010 122

Table 29: Prostate Cancer, Global, Phase III Pipeline, August 2010 130

Table 30: Prostate Cancer, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 139

Table 31: Prostate Cancer, Global, Description of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 140

Table 32: Prostate Cancer, Johnson & Johnson, Oncology Late Stage Pipeline by Indication, 2010 197

Table 33: Prostate Cancer, Global, Auron Healthcare, Key Pipeline Products, 2010 198

Table 34: Prostate Cancer, Global, M&A Deals by Geography, 2010 2081.2

List of Figures

Figure 1: Prostate Cancer Therapeutics Market, Global, Treatment Guidelines, 2010 19

Figure 2: Prostate Cancer Therapeutics Market, US, Sales Value ($m), 2001-2009 20

Figure 3: Prostate Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2001-2009 21

Figure 4: Prostate Cancer Therapeutics Market, US, Patient Volume ('000s), 2001-2009 23

Figure 5: Prostate Cancer Therapeutics Market, US, Treatment Usage Patterns ('000s), 2001-2009 24

Figure 6: Prostate Cancer Therapeutics Market, US, Market Drivers and Restraints, 2009 27

Figure 7: Prostate Cancer Therapeutics Market, The US, Historical Events Impact on the Market, 2010 29

Figure 8: Prostate Cancer Therapeutics Market, US, Sales Value ($m), 2009-2020 30

Figure 9: Prostate Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2009-2020 31

Figure 10: Prostate Cancer Therapeutics Market, US, Patient Volume ('000s), 2009-2020 32

Figure 11: Prostate Cancer Therapeutics Market, US, Treatment Usage Patterns ('000s), 2009-2020 33

Figure 12: Prostate Cancer Therapeutics Market, The US, Future Market Drivers and Restraints, 2010-2020 35

Figure 13: Prostate Cancer Therapeutics Market, US, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020 36

Figure 14: Prostate Cancer Therapeutics Market, US, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2020 38

Figure 15: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Chemotherapy Drugs, 2010 44

Figure 16: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Hormone Therapy Drugs, 2010 45

Figure 17: Prostate Cancer Therapeutics Market, US, Sales Forecast by Therapies, 2001-2020 46

Figure 18: Prostate Cancer, Global, Taxotere, Chemical Structure 48

Figure 19: Prostate Cancer, Global, Taxotere, LCM Activities, 2004-2010 50

Figure 20: Prostate Cancer, US, Taxotere, Sales ($m), 2004-2020 51

Figure 21: Prostate Cancer, Global, Casodex, Chemical Structure 52

Figure 22: Prostate Cancer, Global, Casodex, LCM Activities, 1995-2010 56

Figure 23: Prostate Cancer, US, Casodex, Sales ($m), 1995-2020 57

Figure 24: Prostate Cancer, Global, Zoladex, Chemical Structure 58

Figure 25: Prostate Cancer, US, Zoladex, Sales Forecast ($m), 1998-2020 59

Figure 26: Prostate Cancer, US, Provenge, Sales Forecast ($m), 2010-2020 61

Figure 27: Prostate Cancer, US, Jevtana, Sales Forecast ($m), 2010-2020 62

Figure 28: Prostate Cancer, Global, Eligard , Chemical Structure 63

Figure 29: Prostate Cancer, US, Leuprolide (Eligard, Lupron), Sales Forecast ($m), 2001-2020 67

Figure 30: Prostate Cancer, Global, Lupron, Chemical Structure 68

Figure 31: Prostate Cancer, US, Leuprolide (Eligard, Lupron, Prostap), Sales Forecast ($m), 2001-2020 71

Figure 32: Prostate Cancer, Global, Firmagon, Chemical Structure 72

Figure 33: Prostate Cancer, US, Firmagon, Sales Forecast ($m), 2008-2020 73

Figure 34: Prostate Cancer, Global, Vantas, Chemical Structure 74

Figure 35: Prostate Cancer, US, Vantas, Sales Forecast ($m), 2004-2020 76

Figure 36: Prostate Cancer, Global, Novatrone, Chemical Structure 76

Figure 37: Prostate Cancer, US, Mitoxantrone, Sales Forecast ($m), 2001-2020 78

Figure 38: Prostate Cancer, Global, Emcyt, Chemical Structure 78

Figure 39: Prostate Cancer, US, Estramustine, Sales Forecast ($m), 2001-2020 79

Figure 40: Prostate Cancer, Global, Trelstar, Chemical Structure 80

Figure 41: Prostate Cancer, Global, Eulexin, Chemical Structure 82

Figure 42: Prostate Cancer, Global, Delestrogen, Chemical Structure 84

Figure 43: Prostate Cancer, Global, Gynodiol, Chemical Structure 85

Figure 44: Prostate Cancer, Global, Estrace, Chemical Structure 86

Figure 45: Prostate Cancer, Global, Tace, Chemical Structure 87

Figure 46: Prostate Cancer, Global, Nilandrone, Chemical Structure 88

Figure 47: Prostate Cancer, Global, Premarin, Chemical Structure 89

Figure 48: Prostate Cancer, US, Combined sales of Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol, Sales Forecast ($m), 2001-2020 90

Figure 49: Prostate Cancer, Global, Clinical Trials by Therapy, 2010 91

Figure 50: Prostate Cancer, Global, Clinical Trials by Phase of Development, 2010 92

Figure 51: Prostate Cancer, Global, Pipeline by Mechanism of Action, 2010 93

Figure 52: Prostate Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010 94

Figure 53: Prostate Cancer, Global, Technology Trends Description of Pipeline Drugs, 2010 95

Figure 54: Prostate Cancer, Global, Licensing Agreements by Phase of Development, 2009-2010 96

Figure 55: Prostate Cancer, Global, Licensing Agreements by Geography, 2010 99

Figure 56: Prostate Cancer, Global, Aflibercept, Chemical Structure 102

Figure 57: Prostate Cancer, US, Aflibercept, Sales Forecast ($m), 2013-2020 104

Figure 58: Prostate Cancer, US, Ipilimumab , Sales Forecast ($m), 2014-2020 106

Figure 59: Prostate Cancer, Global, Abiraterone, Chemical Structure 107

Figure 60: Prostate Cancer, US, Abiraterone, Sales Forecast ($m), 2012-2020 109

Figure 61: Prostate Cancer, Global, Zibotentan, Chemical Structure 110

Figure 62: Prostate Cancer, US, Zibotentan , Sales Forecast ($m), 2012-2020 112

Figure 63: Prostate Cancer, US, Sprycel , Sales Forecast ($m), 2013-2020 113

Figure 64: Prostate Cancer, Global, MDV3100, Chemical Structure 114

Figure 65: Prostate Cancer, US, MDV3100 , Sales Forecast ($m), 2012-2020 116

Figure 66: Prostate Cancer, Global, Median Overall Survival for Hormone-independent Metastatic Prostate Cancer Patients, 2010 133

Figure 67: Prostate Cancer, Global, Median Overall Survival for Hormone-dependent Metastatic Prostate Cancer Patients, 2010 134

Figure 68: Prostate Cancer, Global, Hormone-dependent Metastatic Prostate Cancer Patients Achieving Castrate Level Testosterone Level in 28-30 Days (%), 2010 134

Figure 69: Prostate Cancer, US, Prostate Cancer, Opportunity and Unmet Need, 2010 135

Figure 70: Prostate Cancer, US, Hormone-independent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 138

Figure 71: Prostate Cancer, US, Hormone-dependent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 138

Figure 72: Prostate Cancer, Global, Key Events Impacting the Future Market 141

Figure 73: Prostate Cancer, US, Implications for Future Market Competition, 2010 142

Figure 74: Prostate Cancer, Global, Future Players in the Market, 2010 144

Figure 75:Prostate Cancer, Sanofi-aventis, Major Pharmaceutical Drugs 2010 146

Figure 76: Prostate Cancer, Sanofi-aventis Pasteur, Diseases Under Each Vaccination Area 2010 147

Figure 77: Prostate Cancer, Global, Sanofi-aventis, SWOT Analysis, 2010 148

Figure 78: Prostate Cancer, Sanofi-aventis, Therapeutic Segment Share of Pipeline 2010 153

Figure 79: Prostate Cancer, Global, Pfizer, SWOT Analysis 2010 155

Figure 80: Prostate Cancer, Pfizer, Distribution of Pipeline by Phase, 2010 161

Figure 81: Prostate Cancer, Pfizer, Therapeutic Segment Share of Pipeline 2010 162

Figure 82: Prostate Cancer, Astrazeneca, Key Products Portfolio 2010 164

Figure 83: Prostate Cancer, Global, AstraZeneca, SWOT Analysis 2010 165

Figure 84: Prostate Cancer, AstraZeneca, Oncology Products for Different Cancers 2010 169

Figure 85: Prostate Cancer, AstraZeneca, Distribution of Pipeline, by Phase, 2010 169

Figure 86: Prostate Cancer, AstraZeneca, Therapeutic Segment Share of Pipeline 2010 170

Figure 87: Prostate Cancer, Bristol-Myers Squibb, Key Products Portfolio 2010 171

Figure 88: Prostate Cancer, Global, Company Bristol-Myers Squibb, SWOT Analysis, 2010 172

Figure 89: Prostate Cancer, Bristol-Myers Squibb, Distribution of Pipeline by Phase, 2010 178

Figure 90: Prostate Cancer, Bristol-Myers Squibb, Therapeutic Segment Share of Pipeline 2010 179

Figure 91: Prostate Cancer, Global, Medivation, SWOT Analysis 2010 180

Figure 92: Prostate Cancer, Global, Takeda Pahrmaceuticals, SWOT Analysis 2010 184

Figure 93: Prostate Cancer, Global, Dendreon Corporation, SWOT Analysis 2010 186

Figure 94: Prostate Cancer, Global, Johnson and Johnson, SWOT Analysis 2010 191

Figure 95: Prostate Cancer, Johnson & Johnson, Late Stage Pipeline by Therapy Area, 2010 197

Figure 96: Prostate Cancer, Global, GlaxoSmithKline, SWOT Analysis 2010 200

Figure 97: Prostate Cancer, GlaxoSmithKline, Distribution of Pipeline by Phase, 2010 206

Figure 98: Prostate Cancer, GlaxoSmithKline, Therapeutic Segment Share of Pipeline 2010 207

Figure 99: Prostate Cancer, Global, M&A Deals by Geography of Target Companies, 2010 212

Figure 100: Prostate Cancer, Global, M&A Deals by Deal Size, 2010 212

Figure 101: Prostate Cancer, US, Key Data Inputs from KOL Interviews, July 2010 213

Figure 102: GlobalData Market Forecasting Model 220

Companies mentioned

Sanofi-aventis

Pfizer Inc.

AstraZeneca

Bristol-Myers Squibb

Medivation

Takeda Pharmaceuticals

Dendreon Corporation

Johnson and Johnson

Auron Healthcare GmbH

Oncogenex Pharmaceuticals, Inc.

Agennix AG

GTx, Inc.

GlaxoSmithKline plc.

To order this report:

Drug and Medication Industry: Prostate Cancer - US Drug Forecasts and Treatment Analysis to 2020

Drug and Medication Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!


Contact Nicolas Bombourg


Reportlinker


Email: nbo@reportlinker.com


US: (805)652-2626


Intl: +1 805-652-2626


SOURCE Reportlinker
COPYRIGHT 2010 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 8, 2010
Words:4643
Previous Article:New Investment in Flint Featured at Android Open House.
Next Article:Reportlinker Adds Global Generic Pharmaceuticals Industry Report.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters